The United Arab Emirates Infection Control Market - Forecasts from 2020 to 2025
The United Arab Emirates infection control market is projected to grow to US$58.647million by 2025. With the steady growth of population compared to 2017 the Dubai Emirate had 3,080,165 residents in 2018. To cater to the healthcare needs there has been significant growth in the number of physicians and manpower. The registered physicians in Dubai were 8,901 for the year of 2018, with an increase of 57.9% than that of 2011 and an increase of 2.4% than that of 2017. The share of primary health care services is 18.4% and specialized centers 1.4% of the total.
Demand for health services grew at a higher rate during the last few years. This was driven by a significant increase in outpatient encounter as 10,864,076 outpatient visits were recorded during the year of 2018, showing a 3.3% increase than that of 2017. The rate of daily visits was 14.3 visits/1000 population. The Private Health Sector (PHS) represented more than 3-quarters of these visits (78.3%), while the share of Dubai Health Authority was near to one quarter (20%). Thus, translating to achievement of public/private partnership goals in health services provision reached more than the Ratio of 20% Vs. 80% share respectively and achieved Dubai health strategic goals. The number of inpatients in Dubai was 355,327 in 2018, provided through 30 private and 6 governmental hospitals, with an increase of 17.2% in inpatients than that of 2017. The annual discharge rate was 115.4 per 1000/ population. The total bed occupancy rate (BOR) for the Emirate was 54.5%. The number of patients’ days of care was 938,911, with a (16%) increase than total days of care in 2016 [Source: Dubai Annual Health Statistical Report]. Therefore, the aforesaid facts and figures along with burgeoning expenses that are borne by the government along with expenses form the private pocket that contributes to the expenditure mix, to extend various healthcare offerings will require further investments in infection control products to prevent any healthcare-associated infection (HCAI). Thereafter providing the thrust to the clinical infection control market of UAE during the forecast period.
Another segment that is poised to push infection control market growth in UAE to a new zenith during the forecast period is that of the medical tourism and its consequent influence on the hospitality sector through food and beverage as well as an accommodation establishment. To this end, it may be noted that The Health Tourism is a space where the UAE government has put a special emphasis since 2014 when His Highness Sheikh Hamdan Bin Mohammed Bin Rashid Al Maktoum, Crown Prince of Dubai and Chairman of the Dubai Executive Council approved the Dubai Health Tourism Strategy, with Dubai Health Authority (DHA) overseeing its execution. Thus, in order to position Dubai as a globally recognized destination for elective health and wellness treatments, the Health Tourism Council- DHA was formed. Furthermore, the number of overseas patients was 1,207 during the year of 2018. The UK sought overseas treatments by the highest proportion of patients (28.3%), followed by German (25.9%), then followed by Thailand (15.8%) Then USA (6.9%). In the first place, Oncology Treatments were sought by (25.4%) of the total overseas patients. Orthopedic surgery sought by (10.8%), after that, ophthalmology 7.6%, and neurology & neurosurgeries were responsible for 6.7% of cases treated overseas, respectively. The average cost was 274.3 thousand Dirhams per patient. [Source: Dubai Annual Health Statistical Report].
Considering the growth of medical tourism thus the influx of patients from foreign countries, the need for establishments proving food and beverage as well as accommodations and the need for the new healthcare points as well as imperative of legacy healthcare providers to observe and adhere to strict infection prevention measures have emerged as paramount importance. Therefore, the demand for the infection prevention products that will be set in motion by both these symbiotic sectors (healthcare and tourism) is projected to galvanize the Infection Control Market of UAE to unprecedented heights during the forecast period.
Segmentation
Demand for health services grew at a higher rate during the last few years. This was driven by a significant increase in outpatient encounter as 10,864,076 outpatient visits were recorded during the year of 2018, showing a 3.3% increase than that of 2017. The rate of daily visits was 14.3 visits/1000 population. The Private Health Sector (PHS) represented more than 3-quarters of these visits (78.3%), while the share of Dubai Health Authority was near to one quarter (20%). Thus, translating to achievement of public/private partnership goals in health services provision reached more than the Ratio of 20% Vs. 80% share respectively and achieved Dubai health strategic goals. The number of inpatients in Dubai was 355,327 in 2018, provided through 30 private and 6 governmental hospitals, with an increase of 17.2% in inpatients than that of 2017. The annual discharge rate was 115.4 per 1000/ population. The total bed occupancy rate (BOR) for the Emirate was 54.5%. The number of patients’ days of care was 938,911, with a (16%) increase than total days of care in 2016 [Source: Dubai Annual Health Statistical Report]. Therefore, the aforesaid facts and figures along with burgeoning expenses that are borne by the government along with expenses form the private pocket that contributes to the expenditure mix, to extend various healthcare offerings will require further investments in infection control products to prevent any healthcare-associated infection (HCAI). Thereafter providing the thrust to the clinical infection control market of UAE during the forecast period.
Another segment that is poised to push infection control market growth in UAE to a new zenith during the forecast period is that of the medical tourism and its consequent influence on the hospitality sector through food and beverage as well as an accommodation establishment. To this end, it may be noted that The Health Tourism is a space where the UAE government has put a special emphasis since 2014 when His Highness Sheikh Hamdan Bin Mohammed Bin Rashid Al Maktoum, Crown Prince of Dubai and Chairman of the Dubai Executive Council approved the Dubai Health Tourism Strategy, with Dubai Health Authority (DHA) overseeing its execution. Thus, in order to position Dubai as a globally recognized destination for elective health and wellness treatments, the Health Tourism Council- DHA was formed. Furthermore, the number of overseas patients was 1,207 during the year of 2018. The UK sought overseas treatments by the highest proportion of patients (28.3%), followed by German (25.9%), then followed by Thailand (15.8%) Then USA (6.9%). In the first place, Oncology Treatments were sought by (25.4%) of the total overseas patients. Orthopedic surgery sought by (10.8%), after that, ophthalmology 7.6%, and neurology & neurosurgeries were responsible for 6.7% of cases treated overseas, respectively. The average cost was 274.3 thousand Dirhams per patient. [Source: Dubai Annual Health Statistical Report].
Considering the growth of medical tourism thus the influx of patients from foreign countries, the need for establishments proving food and beverage as well as accommodations and the need for the new healthcare points as well as imperative of legacy healthcare providers to observe and adhere to strict infection prevention measures have emerged as paramount importance. Therefore, the demand for the infection prevention products that will be set in motion by both these symbiotic sectors (healthcare and tourism) is projected to galvanize the Infection Control Market of UAE to unprecedented heights during the forecast period.
Segmentation
- By Product
- Disinfectants
- Sterilization
- Low-Temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. THE UNITED ARAB EMIRATES INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. THE UNITED ARAB EMIRATES INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. ASP
8.3. Merck KGaA
8.4. Cardinal Health
8.5. Tuttnauer
8.6. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. THE UNITED ARAB EMIRATES INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. THE UNITED ARAB EMIRATES INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. ASP
8.3. Merck KGaA
8.4. Cardinal Health
8.5. Tuttnauer
8.6. List is not Exhaustive*
